The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations

Gert Van Assche(KU Leuven), James O. Lindsay(Barts Health NHS Trust)

Journal of Crohn s and Colitis

December 22, 2009

10.1016/j.crohns.2009.09.009

Cited by 897

Related Papers

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

|The American Journal of Gastroenterology|2015|1.8k

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

|The Lancet|2022|383

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

|The Lancet|2022|312